Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?
Introduction: Omalizumab is recommended until spontaneous remission occurs rather than for a specific period of time in chronic urticaria (CU). The rate of recurrence of symptoms after treatment varies depending on the method of discontinuation. Objectives: Our study aimed to investigate how the...
Saved in:
| Main Authors: | Petek Üstün, Esra Adışen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mattioli1885
2025-07-01
|
| Series: | Dermatology Practical & Conceptual |
| Subjects: | |
| Online Access: | https://dpcj.org/index.php/dpc/article/view/5196 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Progress in the application of omalizumab in the treatment of chronic inducible urticaria
by: CHEN Ziyan, et al.
Published: (2024-12-01) -
Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria
by: Fikriye Kalkan, et al.
Published: (2025-03-01) -
Omalizumab treatment can increase the serum levels of vitamin D in patients with chronic spontaneous urticaria
by: MENG Zhen, et al.
Published: (2025-03-01) -
Efficiency of Adding Omalizumab to Standard Therapy for Children with Recurrent Spontaneous Urticaria: Comparative Observational Study
by: Vera G. Kalugina, et al.
Published: (2020-08-01) -
Results of Therapy Including Omalizumab in Adolescents With Recurrent Urticaria: Retrospective Cohort Study
by: Vera G. Kalugina, et al.
Published: (2019-09-01)